(Q38611709)

4 September 2017

title

Post-transplantation malignancies: here today, gone tomorrow? (English)

1 reference

4 September 2017

Edward K Geissler

1

1 reference

4 September 2017

language of work or name

English

0 references

publication date

20 October 2015

1 reference

Nature Reviews Clinical Oncology

4 September 2017

published in

1 reference

4 September 2017

volume

12

1 reference

4 September 2017

issue

12

1 reference

4 September 2017

page(s)

705-717

1 reference

De-novo brain tumours in renal-transplant recipients.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer in the transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Malignancy after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer risk in immune-mediated inflammatory diseases (IMID).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Kaposi sarcoma in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cumulative incidence of cancer after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Prostate cancer in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Screening for Prostate, Breast and Colorectal Cancer in Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer screening in elderly patients: a framework for individualized decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Skin cancers after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Skin cancer in organ transplant recipients--where do we stand today?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Skin Cancers and HLA Frequencies in Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Relation between HLA antigens and skin cancer in renal transplant recipients in Queensland, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

On a Possible Protective Effect of HLA-A11 Against Skin Cancer and Keratotic Skin Lesions in Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Risk of malignancy with long-term immunosuppression in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Donor-transmitted malignancies in organ transplantation: assessment of clinical risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Does the immune system naturally protect against cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Prospective study of cancer in patients with hypogammaglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer in children with primary or secondary immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Occurrence of malignancy in immunodeficiency diseases. A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Breakthrough of the year 2013. Cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Regulation of cutaneous malignancy by gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Association of the autoimmune disease scleroderma with an immunologic response to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Effect of immunosuppressive drugs on spontaneous DNA repair in human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Calcineurin inhibitors and rapamycin: cancer protection or promotion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Azathioprine and UVA light generate mutagenic oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Advances in targeting cell surface signalling molecules for immune modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Molecular concepts of virus infections causing skin cancer in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Immunosuppression and Merkel cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus conversion may suppress viral replication in hepatitis C virus-positive renal transplant candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Mycophenolate mofetil inhibits hepatitis C virus replication in human hepatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Epstein-Barr virus infection in adult renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Response: Good ethics require good science: why transplant programs should not disclose misattributed parentage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cyclophilin inhibitors as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Alemtuzumab induction in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

HLA-mismatched renal transplantation without maintenance immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Regulatory immune cells in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

De novo immunosuppression with mammalian target of rapamycin inhibitors and posttransplantation malignancy in focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

mTOR, cancer and transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Mammalian TOR: a homeostatic ATP sensor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

mTOR signaling in cellular and organismal energetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Tor signalling in bugs, brain and brawn

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Fundamental for life: mTOR orchestrates developing biological systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Making new contacts: the mTOR network in metabolism and signalling crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Immunoregulatory functions of mTOR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Regulation of T cells by mTOR: the known knowns and the known unknowns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus enhances the magnitude and quality of viral-specific CD8+ T-cell responses to vaccinia virus vaccination in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

mTOR regulates memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A color-coded reporter model to study the effect of immunosuppressants on CD8+ T-cell memory in antitumor and alloimmune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

mTOR signaling: implications for cancer and anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Minimizing the risk of posttransplant malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus use and cancer incidence among US kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Managing cancer risk and decision making after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Prostate cancer screening and treatment in the transplant population: current status and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer screening in renal transplant recipients: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Treatment of hepatitis C: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Identifying High Risk Groups and Quantifying Absolute Risk of Cancer After Kidney Transplantation: A Cohort Study of 15 183 Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancer After Renal Transplantation: The Next Challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Occurrence of cancer in immune deficiencies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Cancers complicating organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Photocarcinogenesis--DNA damage and gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Lymphomas after solid organ transplantation: a collaborative transplant study report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Tolerogenic therapies in transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

mTOR pathway: A current, up-to-date mini-review (Review).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.186

Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients

31 March 2020

1 reference

12 December 2020

Outcome of rapamycin therapy for post-transplant-lymphoproliferative disorder after kidney transplantation: case series

1 reference

12 December 2020

Malignant lymphomas in transplantation patients

1 reference

12 December 2020

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

1 reference

12 December 2020

'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

Development of cancer in patients with primary immunodeficiencies

1 reference

12 December 2020

Occurrence of cancers in immunosuppressed organ transplant recipients.

1 reference

12 December 2020

The role of angiogenesis in tumor growth

1 reference

12 December 2020

On immunosurveillance in human cancer.

1 reference

12 December 2020

BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12.

1 reference

12 December 2020

Belatacept for kidney transplant recipients

1 reference

12 December 2020

10.1038/NRCLINONC.2015.186

Identifiers

DOI

1 reference

4 September 2017

1 reference